These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 26415225)
1. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition. Yao W; Yue P; Khuri FR; Sun SY Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580 [TBL] [Abstract][Full Text] [Related]
3. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related]
5. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells. Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158 [TBL] [Abstract][Full Text] [Related]
6. The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition. Li B; Ren H; Yue P; Chen M; Khuri FR; Sun SY Cancer Prev Res (Phila); 2012 Apr; 5(4):612-20. PubMed ID: 22345097 [TBL] [Abstract][Full Text] [Related]
7. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells. Zanellato I; Colangelo D; Osella D Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341 [TBL] [Abstract][Full Text] [Related]
8. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer. Pang Y; Bai G; Zhao J; Wei X; Li R; Li J; Hu S; Peng L; Liu P; Mao H J Transl Med; 2022 Jul; 20(1):336. PubMed ID: 35902869 [TBL] [Abstract][Full Text] [Related]
9. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. Chen S; Fu L; Raja SM; Yue P; Khuri FR; Sun SY Mol Cancer; 2010 Jan; 9():23. PubMed ID: 20113484 [TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688 [TBL] [Abstract][Full Text] [Related]
11. Ku70 acetylation and modulation of c-Myc/ATF4/CHOP signaling axis by SIRT1 inhibition lead to sensitization of HepG2 cells to TRAIL through induction of DR5 and down-regulation of c-FLIP. Kim MJ; Hong KS; Kim HB; Lee SH; Bae JH; Kim DW; Dao TT; Oh WK; Kang CD; Kim SH Int J Biochem Cell Biol; 2013 Mar; 45(3):711-23. PubMed ID: 23247197 [TBL] [Abstract][Full Text] [Related]
12. The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. Zhao L; Yue P; Lonial S; Khuri FR; Sun SY Mol Cancer Ther; 2011 Dec; 10(12):2415-25. PubMed ID: 21914854 [TBL] [Abstract][Full Text] [Related]
13. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167 [TBL] [Abstract][Full Text] [Related]
14. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways. Liu X; Wu H; Huang P; Zhang F J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363 [TBL] [Abstract][Full Text] [Related]
15. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma. Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906 [TBL] [Abstract][Full Text] [Related]
17. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Baker EK; Taylor S; Gupte A; Sharp PP; Walia M; Walsh NC; Zannettino AC; Chalk AM; Burns CJ; Walkley CR Sci Rep; 2015 May; 5():10120. PubMed ID: 25944566 [TBL] [Abstract][Full Text] [Related]
18. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Zou W; Liu X; Yue P; Khuri FR; Sun SY Cancer Biol Ther; 2007 Jan; 6(1):99-106. PubMed ID: 17172826 [TBL] [Abstract][Full Text] [Related]
19. Compound C sensitizes Caki renal cancer cells to TRAIL-induced apoptosis through reactive oxygen species-mediated down-regulation of c-FLIPL and Mcl-1. Jang JH; Lee TJ; Yang ES; Min do S; Kim YH; Kim SH; Choi YH; Park JW; Choi KS; Kwon TK Exp Cell Res; 2010 Aug; 316(13):2194-203. PubMed ID: 20451517 [TBL] [Abstract][Full Text] [Related]
20. BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-κB in NSCLC. Shi L; Xiong Y; Hu X; Wang Z; Xie C Int J Med Sci; 2021; 18(14):3090-3096. PubMed ID: 34400879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]